Total Payments
$2,562
2022 Payments
$144.22
Companies
25
Transactions
81
Medicare Patients
420
Medicare Billing
$34,310
Payment Breakdown by Category
Food & Beverage$2,332 (91.0%)
Education$229.57 (9.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,332 | 75 | 91.0% |
| Education | $229.57 | 6 | 9.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $545.46 | 8 | $0 (2020) |
| Boston Scientific Corporation | $440.64 | 6 | $0 (2022) |
| Lilly USA, LLC | $247.36 | 9 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $178.78 | 7 | $0 (2019) |
| Sirtex Medical Inc | $161.85 | 1 | $0 (2018) |
| Genentech USA, Inc. | $159.43 | 5 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $123.58 | 4 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $105.26 | 6 | $0 (2020) |
| Gilead Sciences, Inc. | $86.11 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $77.73 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $144.22 | 1 | Boston Scientific Corporation ($144.22) |
| 2020 | $276.83 | 9 | AbbVie Inc. ($165.35) |
| 2019 | $694.06 | 28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($178.78) |
| 2018 | $919.09 | 22 | BOSTON SCIENTIFIC CORPORATION ($236.37) |
| 2017 | $527.72 | 21 | Lilly USA, LLC ($133.85) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2022 | Boston Scientific Corporation | EXALT Model D (Device) | Food and Beverage | In-kind items and services | $144.22 | General |
| Category: EXALT_ENDO | ||||||
| 11/30/2020 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: VIROLOGY | ||||||
| 10/27/2020 | Alfasigma USA, Inc. | Zelnorm (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: IRRITABLE BOWEL SYNDROME | ||||||
| 10/23/2020 | Boston Scientific Corporation | EXALT MODEL D CONTROLLER (Device) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: THERAPEUTIC IMAGING | ||||||
| 08/17/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: IMMUNOLOGY | ||||||
| 06/24/2020 | Boston Scientific Corporation | EXALT MODEL D CONTROLLER (Device) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: THERAPEUTIC IMAGING | ||||||
| 02/12/2020 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Oncology | ||||||
| 01/15/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Oncology | ||||||
| 01/13/2020 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $124.34 | General |
| 12/11/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Oncology | ||||||
| 12/05/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Oncology | ||||||
| 12/02/2019 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, VENCLEXTA | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: BioOncology/Immunology | ||||||
| 11/13/2019 | Amgen Inc. | KANJINTI (Biological), XGEVA | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Oncology | ||||||
| 10/03/2019 | Genentech USA, Inc. | Avastin (Biological) | Education | In-kind items and services | $99.00 | General |
| Category: BioOncology | ||||||
| 09/26/2019 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: BioOncology | ||||||
| 09/18/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Oncology | ||||||
| 09/10/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/04/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Hematology / Oncology | ||||||
| 08/28/2019 | GENZYME CORPORATION | GAUCHER-DISEASE (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| 08/21/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Oncology | ||||||
| 07/25/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $117.30 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/19/2019 | Amgen Inc. | Prolia (Biological), XGEVA | Food and Beverage | In-kind items and services | $11.67 | General |
| Category: Bone Health | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 80 | 94 | $29,512 | $7,813 |
| 2022 | 3 | 53 | 63 | $15,470 | $5,470 |
| 2020 | 8 | 287 | 337 | $182,168 | $21,028 |
Total Patients
420
Total Services
494
Medicare Billing
$34,310
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $8,840 | $3,132 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 36 | $5,400 | $2,273 | 42.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 21 | 21 | $12,852 | $1,522 | 11.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $2,420 | $886.60 | 36.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $8,840 | $2,970 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 25 | $3,750 | $1,647 | 43.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $2,880 | $853.41 | 29.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 68 | 105 | $39,276 | $6,004 | 15.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 91 | 103 | $18,227 | $3,962 | 21.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 30 | 30 | $16,676 | $2,875 | 17.2% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Facility | 2020 | 16 | 16 | $13,675 | $2,206 | 16.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 36 | 37 | $51,324 | $2,185 | 4.3% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 16 | 16 | $24,336 | $2,027 | 8.3% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 15 | 15 | $14,339 | $1,063 | 7.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 15 | 15 | $4,315 | $705.31 | 16.3% |
About Dr. Leon Yoder, DO
Dr. Leon Yoder, DO is a Gastroenterology healthcare provider based in Wagoner, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285621482.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leon Yoder, DO has received a total of $2,562 in payments from pharmaceutical and medical device companies, with $144.22 received in 2022. These payments were reported across 81 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($2,332).
As a Medicare-enrolled provider, Yoder has provided services to 420 Medicare beneficiaries, totaling 494 services with total Medicare billing of $34,310. Data is available for 3 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Wagoner, OK
- Active Since 10/03/2005
- Last Updated 08/30/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1285621482
Products in Payments
- CYRAMZA (Drug) $164.20
- SIR-Spheres Microspheres (Device) $161.85
- XIFAXAN (Drug) $149.84
- EXALT Model D (Device) $144.22
- CAPTIVATOR COLD (Device) $122.23
- TRULANCE (Drug) $117.30
- Avastin (Biological) $114.16
- WALLFLEX (Device) $114.14
- Creon (Drug) $92.89
- Epclusa (Drug) $86.11
- ALIMTA (Drug) $83.16
- MEKINIST (Drug) $62.88
- OPDIVO (Biological) $58.94
- EXALT MODEL D CONTROLLER (Device) $42.81
- INJECTAFER (Drug) $40.77
- Stivarga (Drug) $37.06
- GAUCHER-DISEASE (Drug) $35.75
- Braftovi (Drug) $32.98
- Revlimid (Drug) $30.87
- HUMIRA (Biological) $27.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.